Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)

BACKGROUND: Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein–mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal s...

Descripción completa

Detalles Bibliográficos
Autores principales: Michael Gibson, C., Korjian, Serge, Tricoci, Pierluigi, Daaboul, Yazan, Yee, Megan, Jain, Purva, Alexander, John H., Steg, P. Gabriel, Lincoff, A. Michael, Kastelein, John J.P., Mehran, Roxana, D’Andrea, Denise M., Deckelbaum, Lawrence I., Merkely, Bela, Zarebinski, Maciej, Ophuis, Ton Oude, Harrington, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147036/
https://www.ncbi.nlm.nih.gov/pubmed/27881559
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147036/
https://www.ncbi.nlm.nih.gov/pubmed/27881559
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025687

Ejemplares similares